Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia, Paul Mitchell, Alexander Dobrovic, Thomas John
Clinical Epidemiology | DOVE MEDICAL PRESS LTD | Published : 2014
AD has received funding from Cancer Australia and the Cancer Council of Victoria. TJ is an NHMRC early career fellow and receives funding through the Victorian Cancer Agency and Cancer Council.